L
2.58
0.04 (1.57%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Larimar Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.3
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | -4.0 |
| 相对估值 | NA |
| 财务健康 | NA |
| 宏观环境 | -0.3 |
| AI Insight | NA |
| 平均 | 0.31 |
|
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.43% |
| 机构持股比例 | 103.11% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Blue Owl Capital Holdings Lp | 30 Jun 2026 | 9,163,157 |
| Defilade Capital Management, L.P. | 30 Jun 2026 | 3,670,135 |
该时间范围内无数据。
该时间范围内无数据。
投资组合